Foster City, Calif., 3 Oct 2024:  Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir.

 

Before filing for global regulatory approvals, the company has lined ......
View Details

Related News

• Centre to amend Rules to tackle submission of forged data or documents (09-10-2024)

---

• More FDCs may be banned; experts found that many lack therapeutic justification (09-10-2024)

---

• DCGI wants qualified medical device testing officers (09-10-2024)

---

• Govt waives testing of cough syrups for export to key markets (09-10-2024)

---

• Illegal to advertise Ayurveda, Siddha drugs claiming 'miraculous' effects: Ayush ministry (08-10-2024)

---

• Fake and banned medicines recovered from Pradhan Mantri Jan Aushadhi Kendra, Aliganj (08-10-2024)

---

• 2 held in Amberpet with 84 Fake educational certificates (08-10-2024)

---

• Drug Menace: P&H HC directs CBI to enquire into Large-Scale Manufacturing of Tablets by Pharma Firms in HP (08-10-2024)

---

• Drug capsules being sold as Blue Ford, Green Parrot and John Deere will be banned (08-10-2024)

---

• Rajesh Narvekar takes charge as FDA Commissioner of Maharashtra (08-10-2024)

---